Evidence map›Paper›PMID 29198826›Full record

ArticleStem cell reports2017

TRIM28 and Interacting KRAB-ZNFs Control Self-Renewal of Human Pluripotent Stem Cells through Epigenetic Repression of Pro-differentiation Genes.

Urszula Oleksiewicz, Marta Gładych, Ayush T Raman, Holger Heyn, Elisabetta Mereu, Paula Chlebanowska, Anastazja Andrzejewska, Barbara Sozańska, Neha Samant, Katarzyna Fąk and 11 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 106 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Clinical translation of epigenome editing technologies.Current opinion in biomedical engineering · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Coupling of stemness maintenance with cell cycle control in stem cells.Frontiers in cell and developmental biology · 2025
    Review
  19. Multifaceted role ofMedComm · 2024
    Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 3 countries.

Urszula OleksiewiczLaboratory for Gene Therapy, Department of Cancer Immunology, Poznan University of Medical Sciences, 60-806 Poznan, Poland; Laboratory for Gene Therapy, Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland.
Marta GładychLaboratory for Gene Therapy, Department of Cancer Immunology, Poznan University of Medical Sciences, 60-806 Poznan, Poland; Laboratory for Gene Therapy, Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland.
Ayush T RamanGraduate Program in Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, TX 77030, USA; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Holger HeynCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona 08908, Catalonia, Spain; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona 08036, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Elisabetta MereuCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona 08036, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Paula ChlebanowskaLaboratory for Gene Therapy, Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland; University of Life Sciences, 60-637 Poznan, Poland.
Anastazja AndrzejewskaLaboratory for Gene Therapy, Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland; Adam Mickiewicz University, Biology Department, 61-614 Poznan, Poland.
Barbara SozańskaFaculty of Mathematics and Information Science, Warsaw University of Technology, 00-602 Warsaw, Poland.
Neha SamantDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Katarzyna FąkFaculty of Mathematics and Information Science, Warsaw University of Technology, 00-602 Warsaw, Poland.
Paulina AuguścikFaculty of Mathematics and Information Science, Warsaw University of Technology, 00-602 Warsaw, Poland.
Marcin KosińskiFaculty of Mathematics and Information Science, Warsaw University of Technology, 00-602 Warsaw, Poland.
Joanna P WróblewskaLaboratory for Gene Therapy, Department of Cancer Immunology, Poznan University of Medical Sciences, 60-806 Poznan, Poland; Laboratory for Gene Therapy, Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland.
Katarzyna TomczakLaboratory for Gene Therapy, Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland; Postgraduate School of Molecular Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Katarzyna KulcentyLaboratory for Gene Therapy, Department of Cancer Immunology, Poznan University of Medical Sciences, 60-806 Poznan, Poland; Laboratory for Gene Therapy, Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland.
Rafał PłoskiDepartment of Medical Genetics, Medical University of Warsaw, 02-091 Warsaw, Poland.
Przemysław BiecekFaculty of Mathematics and Information Science, Warsaw University of Technology, 00-602 Warsaw, Poland; Warsaw Faculty of Mathematics, Informatics, and Mechanics, University of Warsaw, 02-097 Warsaw, Poland.
Manel EstellerCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona 08908, Catalonia, Spain; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona 08907, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Catalonia, Spain.
Parantu K ShahInstitute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Kunal RaiDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. Electronic address: krai@mdanderson.org.
Maciej WiznerowiczLaboratory for Gene Therapy, Department of Cancer Immunology, Poznan University of Medical Sciences, 60-806 Poznan, Poland; Laboratory for Gene Therapy, Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland. Electronic address: wiznerowicz@ump.edu.pl.
The University of Texas MD Anderson Cancer Center · USWarsaw University of Technology · PLGreater Poland Cancer Center · PLPoznan University of Medical Sciences · PLCentre for Genomic Regulation · ESAdam Mickiewicz University in Poznań · PLMedical University of Warsaw · PLUniversitat de Barcelona · ESUniversity of Life Sciences in Poznań · PLUniversity of Warsaw · PL

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Reprogramming to induced pluripotent stem cells (iPSCs) and differentiation of pluripotent stem cells (PSCs) are regulated by epigenetic machinery. Tripartite motif protein 28 (TRIM28), a universal mediator of Krüppel-associated box domain zinc fingers (KRAB-ZNFs), is known to regulate both processes; however, the exact mechanism and identity of participating KRAB-ZNF genes remain unknown. Here, using a reporter system, we show that TRIM28/KRAB-ZNFs alter DNA methylation patterns in addition to H3K9me3 to cause stable gene repression during reprogramming. Using several expression datasets, we identified KRAB-ZNFs (ZNF114, ZNF483, ZNF589) in the human genome that maintain pluripotency. Moreover, we identified target genes repressed by these KRAB-ZNFs. Mechanistically, we demonstrated that these KRAB-ZNFs directly alter gene expression of important developmental genes by modulating H3K9me3 and DNA methylation of their promoters. In summary, TRIM28 employs KRAB-ZNFs to evoke epigenetic silencing of its target differentiation genes via H3K9me3 and DNA methylation.

Indexed as

Binding SitesCell DifferentiationCell Self RenewalCellular ReprogrammingDNA MethylationEpigenetic RepressionGene Expression Regulation, DevelopmentalHistone-Lysine N-MethyltransferaseHumansPluripotent Stem CellsPromoter Regions, GeneticRepressor ProteinsTripartite Motif-Containing Protein 28Histone-Lysine N-MethyltransferaseRepressor ProteinsTRIM28 protein, humanTripartite Motif-Containing Protein 28ZNF350 protein, humanZNF589 protein, humandifferentiationepigeneticsinduced pluripotent stem cellsKRAB-ZNF repressorsreprogrammingTRIM28

Identifiers

PMID29198826
PMCPMC5785758
OpenAlexW2775397399

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.